Update 11/8: Reported record 2Q26 revenue of US$21.7m (+18% YoY, +13% QoQ), driven by US RECELL unit volume growth and contributions from Cohealyx and PermeaDerm. Management upgraded FY26 revenue guidance to US$86-89m and anticipates cash-flow breakeven in 4Q26.
Avita Medical Hold
Buying interest is from a series of positive clinical, operational, and financial milestones that have renewed investor confidence in the company’s commercial execution and path to profitability.
Avita Medical is a commercial-stage regenerative medicine company focused on acute wound care and therapeutic skin restoration.
Revenue Growth: Q1 2026 revenue reached $19.3 million USD, a 4% year-over-year increase and a 10% sequential increase from Q4 2025, showing gradual recovery following reimbursement and distribution disruptions in late 2025.
Level 17 Chifley Tower
2 Chifley Square
Sydney, NSW 2000
1300 614 002
Investor Signals Pty Ltd
ABN 44 143 555 453